CG Oncology, Inc.

For the period ended Dec 31, 2024. Filed Mar 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 28, 2025

CGON$72.64-2.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2024 and 2023

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	December 31,
Assets	2024	2023
Current assets:
Cash and cash equivalents	$257,068	$8,266
Marketable securities	484,930	179,408
Prepaid expenses and other current assets	11,431	6,358
Accounts receivable - other	781	92
Total current assets	754,210	194,124
Property and equipment, net	272	69
Operating lease right-of-use assets	221	422
Other assets	94	19
Deferred offering costs	—	4,667
Total assets	$754,797	$199,301
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$6,517	$3,242
Success fee liability, current portion	—	352
Operating lease liabilities, current portion	186	217
Accrued expenses and other current liabilities	14,665	10,443
Total current liabilities	21,368	14,254
Success fee liability, non-current	—	13
Operating lease liabilities, net of current portion	52	244
Total liabilities	21,420	14,511
Commitments and contingencies (Note 5)
Redeemable convertible preferred stock:
Series A-1 redeemable convertible preferred stock, $0.0001 par value per share; zero and 5,075,000 shares authorized, issued and outstanding as of December 31, 2024 and December 31, 2023, respectively; liquidation value of $0 and $3,570 as of December 31, 2024 and December 31, 2023, respectively	—	3,570
Series B redeemable convertible preferred stock, $0.0001 par value per share; zero and 11,973,000 shares authorized, issued and outstanding as of December 31, 2024 and December 31, 2023; liquidation value of $0 and $10,000 as of December 31, 2024 and December 31, 2023, respectively	—	10,000
Series C redeemable convertible preferred stock, $0.0001 par value per share; zero and 73,598,283 shares authorized, issued and outstanding as of December 31, 2024 and December 31, 2023, respectively; liquidation value of $0 and $22,000 as of December 31, 2024 and December 31, 2023, respectively	—	22,000
Series D redeemable convertible preferred stock, $0.0001 par value per share; zero and 53,271,754 shares authorized, issued and outstanding as of December 31, 2024 and December 31, 2023, respectively; liquidation value of $0 and $47,300 as of December 31, 2024 and December 31, 2023, respectively	—	47,300
Series E redeemable convertible preferred stock, $0.0001 par value per share; zero and 112,422,700 shares authorized, issued and outstanding as of December 31, 2024 and December 31, 2023, respectively; liquidation value of $0 and $120,000 as of December 31, 2024 and December 31, 2023, respectively	—	120,000
Series F redeemable convertible preferred stock, $0.0001 par value per share; zero and 81,587,937 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively; liquidation value of zero and $105,020 as of December 31, 2024 and December 31, 2023, respectively	—	105,020
Stockholders’ equity (deficit):
Common stock, $0.0001 par value per share; 700,000,000 and 493,530,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 76,154,783 and 5,222,283 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	8	—
Additional paid-in capital	951,350	6,842
Accumulated deficit	(217,981)	(129,942)
Total stockholders' equity (deficit)	733,377	(123,100)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$754,797	$199,301

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.